Ascendis Pharma A/S ADR ASND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASND is a good fit for your portfolio.
News
-
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
-
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
-
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
-
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
-
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
-
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
-
Ascendis Shares Rally Premarket as FDA Doesn't Seek New Studies
Trading Information
- Previous Close Price
- $143.17
- Day Range
- $136.53–140.69
- 52-Week Range
- $66.45–160.12
- Bid/Ask
- $137.92 / $138.35
- Market Cap
- $7.82 Bil
- Volume/Avg
- 199,644 / 345,279
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 27.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 879
- Website
- https://www.ascendispharma.com
Valuation
|
Metric
|
ASND
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 27.92 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASND
|
|---|---|
Quick Ratio | 2.31 |
Current Ratio | 3.56 |
Interest Coverage | −10.14 |
Quick Ratio
ASND
Profitability
|
Metric
|
ASND
|
|---|---|
Return on Assets (Normalized) | −47.48% |
Return on Equity (Normalized) | −786.88% |
Return on Invested Capital (Normalized) | −66.57% |
Return on Assets
ASND
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lpzzqjwhdr | Jpft | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pzsfrzstx | Shvnlk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dhjfvbhm | Rrltyt | $99.5 Bil | |
MRNA
| Moderna Inc | Bclnywym | Chrn | $38.8 Bil | |
ARGX
| argenx SE ADR | Qvrrzhh | Hgsw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jptnhmzll | Sby | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wmhbdnfq | Pvqhlh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dgjmmfk | Vvjskq | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Syqfrrrnc | Gttjjrv | $12.5 Bil | |
INCY
| Incyte Corp | Xfnbnypz | Lhwbjw | $11.6 Bil |